New Frontiers in the
Science and Management of
Metastatic Breast Cancer

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Participation and Request for Credit:

There are no fees for participating and receiving CME credit for this activity. During the period August 30, 2011 through August 30, 2012, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Estimated Time to Complete Educational Activity:

2.0 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of metastatic breast cancer.

Release Date:

August 30, 2011

Expiration Date:

August 30, 2012

Intended Audience:

This complimentary CME educational activity is designed for all physicians, academicians, researchers, investigators, support staff, nurses, and program directors from the fields of oncology, with a special interest in breast cancer.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Jointly sponsored by Postgraduate Institute for Medicine and CMEducation. www.pimed.com

Supported by an independent
educational grant from
Eisai, Inc

Physician Continuing Education:

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and CMEducation Resrouces. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Program Faculty and Disclosures:

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

JOSEPH A. SPARANO, MD — Program Chair
Professor, Departments of Obstetrics, Gynecology, and Women's Health
Departments of Medicine and Oncology
Chief, Section of Breast Medical Oncology, Montefiore-Einstein Cancer Center
Chair, Albert Einstein Cancer Center Breast Cancer Working Group
Associate Chairman, Department of Oncology, Montefiore Medical Center
New York, New York USA

Speaker’s Bureau: BMS
Grant/Research Support: Eisai


STEFAN GLÜCK, MD, PhD, FRCPC
Sylvester Professor, Department of Medicine
Assistant Director, Sylvester Comprehensive Cancer Center
Associate Chief, Division of Hematology/Oncology
University of Miami, Leonard M. Miller School of Medicine
Miami, Florida USA

Consultant: Genentech, Roche, GSK, Genomic Health, Eli Lilly, Novartis, Pfizer, Abraxis
Speaker’s Bureau: Genentech, Roche, GSK, Genomic Health, Eli Lilly, Novartis, Pfizer, Abraxis
Grant/Research Support: Genentech, Roche, GSK, Genomic Health, Eli Lilly, Novartis, Pfizer, Abraxis


JAVIER CORTES, MD
Professor of Medicine
Department of Oncology
Vall d’Hebron University Hospital
Barcelona, Spain

Consultant: Roche


MARY ANN JORDAN, PhD
Adjunct Professor and Research Biologist
Department of Molecular, Cellular and Developmental Biology
Neuroscience Research Institute
Previously, Chair, California Breast Research Program
University of California

Investigator: BMS, Eisai

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Educational Objectives:

After completing this activity, the participant should be better able to:

• Discuss evidence-based strategies that can prolong survival in patients with metastatic breast cancer (MBC) who have received multiple, established chemotherapeutic treatment courses (i.e., heavily treated) with documented remissions
• Detail the safety, efficacy, and survival prolongation profiles associated with novel treatments being evaluated for MSB, including the role of nontaxane, microtubule dynamics inhibitors
• Describe the tolerability factors, outcomes, and evidence-based rationale for the use of microtubule inhibitors in heavily pretreated women with metastatic breast cancer who had already received treatment with anthracycline and a taxane for MBC
• Discuss rationale, combination therapy, trial design, and outcome metrics focused on progression-free survival and overall survival in heavily treated patients with MBC
• Compare the tolerability, safety, and impact on clinical outcomes of late stage agents for MBC, focusing on comparative value of taxanes versus novel agents (microtubule inhibitors) when used as combination therapy with anthracyclines and similar settings
• Compare the side effect profiles of anti-tumor agents used for poorly responsive MBC, focusing on such adverse effects as alopecia and peripheral neuropathy
• List approaches to sequencing chemotherapeutic agents for MBC—including anthracyclines, taxanes, capecitabine, and novel microtubule-inhibiting agents
• Explain which add-on agents in heavily treated patients with MBC are most effective in prolonging survival and maintaining end-of-live, quality-of-life (QoL)
• Compare the side effects of agents (taxanes, capecitabine) to halichondrin B-based inhibitors of microtubule dynamics, and how the mechanism of action that produce microtubule growth suppression can impact side effect profiles, overcome drug resistance observed with standard agents used for sequenced therapy, and prolong survival in MBC
  

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), CMEducation Resources and Eisai, Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMEducation Resources and Eisai, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Copyright © 2011 Resources, LLC All rights reserved.